Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL PDM vs ALIQOPA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
Relapsed follicular lymphoma (FDA accelerated approval) in patients who have received at least two prior systemic therapies,Off-label: Other B-cell malignancies (e.g., diffuse large B-cell lymphoma, chronic lymphocytic leukemia)
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life of approximately 39 hours in patients with hematologic malignancies; supports twice-daily dosing.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Primarily fecal (88%) and renal (8%) as unchanged drug and metabolites; biliary excretion contributes significantly.
98% bound to albumin.
84% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Apparent volume of distribution approximately 217 L in patients, indicating extensive extravascular distribution.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Oral bioavailability approximately 34% under fasted conditions; food increases exposure (AUC) by 34% but decreases Cmax by 11%.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
For GFR ≥ 30 m L/min: no adjustment. For GFR < 30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 40 mg; Child-Pugh C: avoid use.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Safety and efficacy not established; no recommended dose.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
No specific dose adjustment; monitor for increased toxicity due to age-related renal impairment.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
Fatal and serious toxicities including infections, hyperglycemia, hypertension, non-infectious pneumonitis, and severe cutaneous reactions have occurred.
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Monitor for infections; manage hyperglycemia and hypertension; monitor for pneumonitis symptoms; avoid in patients with severe hepatic impairment.
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
None known, but caution in patients with severe hepatic impairment (Child-Pugh C) and those with active serious infections.
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
Avoid grapefruit, grapefruit juice, and Seville oranges as they may increase drug exposure. No other specific food interactions reported.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, copanlisib was teratogenic and embryotoxic at maternal exposures below the recommended human dose. First trimester: High risk of structural anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios; potential for fetal PI3K pathway disruption. Advise women of childbearing potential to use effective contraception during treatment and for at least 1 month after the last dose.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
No data on the presence of copanlisib in human milk, its effects on the breastfed child, or on milk production. Due to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 1 month after the last dose. M/P ratio: unknown.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
No specific dosing adjustments for pregnancy are established. The physiological changes of pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may affect copanlisib pharmacokinetics, but data are lacking. Use during pregnancy should be avoided unless the potential benefit outweighs the risk. If treatment is necessary, consider therapeutic drug monitoring if available, and monitor for toxicity.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
ALIQOPA (copanlisib) is a PI3K inhibitor with significant toxicity including hyperglycemia, hypertension, and infections. Monitor blood glucose and blood pressure closely during infusion. Premedicate with antihistamines and corticosteroids to reduce infusion-related reactions. Consider Pneumocystis jirovecii pneumonia prophylaxis due to immunosuppression.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
Report any signs of infection (fever, cough, burning urination) immediately.,Monitor blood sugar levels regularly as this drug can cause high blood sugar.,Check blood pressure at home and report elevations.,Avoid grapefruit and Seville oranges during treatment.,Use effective contraception during treatment and for 1 month after last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL PDM vs ALIQOPA, answered by our medical review team.
BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. ALIQOPA is a PI3K Inhibitor Antineoplastic that works by ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL PDM and ALIQOPA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. The standard adult dose of ALIQOPA is: 60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL PDM and ALIQOPA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . ALIQOPA is classified as Category C. ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.